Skip to main content

Biometry

Contributes to the rigor and reproducibility of cancer research through statistical consultation and mathematical modeling. Supports research in biostatistical methods and data analytics, machine learning, and artificial intelligence for cancer risk prediction and reduction.

On This Page

All Heading 2s will automatically be pulled in to this list.
Do not edit the content on this template.

Resources

Staff List

Grid View

Photo	Name, Email, Phone	Room	Group(s)/Office
	Berger, Vance, Ph.D. vance.berger@nih.gov 240-276-7142	5E628	Statistician \| Biometry
	Bowles, Heather, Ph.D. heather.bowles@nih.gov 240-276-6794	5E640	Program Officer \| Biometry Cancer Prevention Fellowship Program
	Dodd, Kevin, Ph.D. kevin_dodd@nih.gov 240-276-7021	5E126	Deputy Chief \| Biometry
	Hu, Ping, Sc.D. ping.hu@nih.gov 240-276-7015	5E118	Statistician \| Biometry
	Morris, Lawrence lawrence.morris@nih.gov 240-276-7137	5E112	Program Specialist \| Biometry
	Prorok, Philip C, Ph.D. [C] philip.prorok@nih.gov 240-276-7131		Contractor \| Office of the Director Biometry
	Sirota, Lev, Ph.D. [C] lev.sirota@nih.gov 240-276-5127	5E114	Contractor \| Biometry
	Uzzell, Norwood norwood.uzzell@nih.gov 240-276-7141	5E222	Program Support Assistant \| Biometry
	Xu, Jian-Lun, Ph.D. jian-lun.xu@nih.gov 240-276-7023	5E128	Statistician \| Biometry

Grants

PI Name Sort descending	PI Organization	Title	Grant Number	Program Official
Skates, Steven J	Massachusetts General Hospital United States	Genome-wide methylation and proteomic analysis of uterine lavage and cervical swab for early detection of ovarian cancer	5U2CCA271871-03	Christos Patriotis, Ph.D., M.Sc.
Skubitz, Amy Patrice	University Of Minnesota United States	A paradigm shift for ovarian cancer biomarkers: Utilizing routine Pap tests as liquid biopsies for the development of targeted mass spectrometry-based proteomic assays for early detection	5R01CA262153-05	Christos Patriotis, Ph.D., M.Sc.
Slager, Susan L	Mayo Clinic Rochester United States	The genetic and epigenetic etiology of progression from the precursor state to chronic lymphocytic leukemia (CLL)	4R01CA258465-04	Nicholas Hodges, Ph.D.
Smith, Ellen Mary Lavoie	University Of Alabama At Birmingham United States	Duloxetine to Prevent Oxaliplatin-Induced Chemotherapy-Induced Peripheral Neuropathy: A Randomized, Double-Blind, Placebo-Controlled Phase II to Phase III Study	5R01CA235726-07	Brennan Streck, Ph.D., RN, M.P.H.
Smith, Jennifer Susan	Univ Of North Carolina Chapel Hill United States	UNC CASCADE Network Research Base	5UG1CA275403-04	Maria Silvina Frech, Ph.D., M.S.
Sohl, Stephanie Jean	Wake Forest University Health Sciences United States	REmotely-delivered Supportive Programs for Improving surgical pain and disTrEss (RESPITE)	5R01CA266995-04	Goli Samimi, Ph.D., M.P.H.
Somers, Tamara J	Duke University United States	A Mobile Health Behavioral Pain Intervention Protocol for Breast Cancer Patients with Pain in Medically Underserved Communities: A Randomized Controlled Trial	5R01CA237892-05	Brennan Streck, Ph.D., RN, M.P.H.
Song, Ming	University Of Louisville United States	Dietary fructose and NASH/HCC progression	5R21CA290420-02	Amit Kumar, Ph.D.
Sorror, Mohamed	Fred Hutchinson Cancer Center United States	Novel Intervention Approaches to Alleviate Allogeneic Transplant-Related Morbidity and Mortality	5R01CA227092-06	Marjorie Perloff, M.D.
Spector, Tim	King'S College London United States	PROSPECT: Pathways, Risk factors, and mOleculeS to Prevent Early-onset Colorectal Tumors	1OT2CA297289-01	Asad Umar, D.V.M., Ph.D.
Spiegel, Brennan	Cedars-Sinai Medical Center United States	Randomized Controlled Trial of Virtual Reality for GI Cancer Pain to Improve Patient Reported Outcomes	5R01CA252211-05	Rachel Altshuler, Ph.D.
Stachler, Matthew D	University Of California, San Francisco United States	Optimization and validation of a biomarker panel for risk stratification in Barrett's esophagus	3R37CA269649-03S1	Matthew Young, Ph.D.
Staff, Nathan P	Mayo Clinic Rochester United States	Investigating the role of MAP2 in chemotherapy-induced peripheral neurotoxicity	5R01CA275870-03	Rachel Altshuler, Ph.D.
Stolley, Melinda R	Medical College Of Wisconsin United States	Every Day Counts: A lifestyle program for women metastatic breast cancer	5R01CA258759-04	Nancy J. Emenaker, Ph.D., RDN, LD, FAND
Storz, Peter	Mayo Clinic Jacksonville United States	Deiminated molecules as markers for developing pancreatic cancer - A1	5R21CA279916-02	Matthew Young, Ph.D.